Pre-procedural elevated cardiac troponin predict risk of long-term all-cause mortality after transcatheter aortic valve replacement: a meta-analysis of prospective studies

Biomarkers. 2020 Mar;25(2):164-170. doi: 10.1080/1354750X.2020.1714736. Epub 2020 Jan 24.

Abstract

Background: The purpose of this meta-analysis was to evaluate the relationship between elevated cardiac troponin pre-transcatheter aortic valve replacement (TAVR) and long-term all-cause mortality.Methods: Prospective studies with the endpoint of all-cause mortality were included. We primarily used the fixed-effect model weighted by inverse variance. Meta-regression and subgroup analyses were conducted to explore the potential sources of heterogeneity by specified study characteristics.Results: Seven prospective studies comprising of 3049 subjects were included in our meta-analysis. Pre-procedural elevated cardiac troponin was associated with increased risk of long-term mortality post TAVR [hazard ratio (HR) 2.25, 95% CI 1.83-2.78, p = 0.000, I2 = 30.3%, p for heterogeneity 0.197]. In addition, subgroup analyses have shown that the group with an younger age (<82 y) seemed to have a higher risk of all-cause mortality than the group with older age (≥82 y) [HR 4.08 (2.41 to 6.89) VS 2.01 (1.60 to 2.53), p = 0.016 for subgroup difference].Conclusions: Pre-procedural elevated cardiac troponin was associated with increased long-term all-cause mortality in patients undergoing TAVR.

Keywords: TAVR; Troponin; meta-analysis; mortality; myocardial injury.

Publication types

  • Meta-Analysis

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Male
  • Preoperative Period
  • Prospective Studies
  • Risk Assessment
  • Transcatheter Aortic Valve Replacement / mortality*
  • Troponin I / blood*

Substances

  • Troponin I